Cleveland, OH, United States of America

Thomas Radivoyevitch

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Thomas Radivoyevitch

Introduction

Thomas Radivoyevitch is a notable inventor based in Cleveland, Ohio. He has made significant strides in the field of cancer treatment through his innovative research and development. His work focuses on the modulation of TET2, a critical factor in cancer therapy.

Latest Patents

Radivoyevitch holds a patent for "Antitumor TET2 Modulating Compounds." This patent describes a method of treating cancer by administering a therapeutically effective amount of a TET2 activating compound or its pharmaceutically acceptable salt to a subject in need of treatment. The TET2 activating compounds are identified as α-ketoglutarate derivatives. Additionally, the patent outlines a method for treating or preventing cancer that includes analyzing a biological sample to determine if cells exhibit a TET2 mutation, alongside administering a TET2 activator.

Career Highlights

Radivoyevitch is affiliated with the Cleveland Clinic Foundation, where he contributes to groundbreaking research in oncology. His work has the potential to change the landscape of cancer treatment, providing new avenues for therapy that could improve patient outcomes.

Collaborations

Some of his notable coworkers include Jaroslaw Maciejewski and Babal Kant Jha, who collaborate with him on various research projects aimed at advancing cancer treatment methodologies.

Conclusion

Thomas Radivoyevitch's contributions to cancer research through his innovative patent demonstrate his commitment to improving therapeutic options for patients. His work at the Cleveland Clinic Foundation highlights the importance of collaboration in the pursuit of medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…